Welcome to our dedicated page for Axsome Therapeut SEC filings (Ticker: AXSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Axsome Therapeutics, Inc. (NASDAQ: AXSM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a biopharmaceutical issuer focused on central nervous system (CNS) conditions, Axsome uses its SEC reports to communicate financial results, product revenue for AUVELITY, SUNOSI, and SYMBRAVO, and updates on its development pipeline, which includes programs such as AXS-05, AXS-12, AXS-14, solriamfetol in new indications, and AZD7325.
Among the filings, Form 8-K current reports are especially relevant for tracking material events. For example, Axsome has filed 8-Ks to furnish press releases announcing quarterly financial results and to disclose updates such as the receipt of a Paragraph IV Certification Notice Letter regarding a proposed generic version of SYMBRAVO. These documents help investors understand how clinical progress, intellectual property developments, and commercial performance affect the company.
In addition to 8-Ks, investors typically review Axsome’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain detailed discussions of net product revenue, research and development spending, selling and administrative expenses, risk factors, and descriptions of the company’s CNS portfolio and pipeline. Proxy statements and, when applicable, Forms 3, 4, and 5 can provide information on insider holdings and transactions, while registration statements and prospectuses outline capital-raising activities.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents such as 10-Ks, 10-Qs, and major 8-Ks in plain language. Real-time EDGAR updates help ensure that new Axsome filings appear promptly, and AI-generated highlights can make it easier to locate information on topics such as AXS-05’s regulatory status, AXS-12’s Orphan Drug Designation, or revenue trends for AUVELITY, SUNOSI, and SYMBRAVO without reading every page of the underlying filing.
Insider notice of proposed sale: This Form 144 reports a proposed sale of 9,127 shares of common stock of Axsome Therapeutics, Inc. via Charles Schwab & Co., Inc. valued at $1,141,529.00. The filing shows the shares were acquired and are proposed to be sold on 09/05/2025 following an employee stock option exercise and that payment was handled by broker payment for cashless exercise. The filing indicates there were 49,901,487 shares outstanding and names NASDAQ as the exchange for the sale. No securities of the issuer were reported sold by the filer in the past three months and other standard Form 144 declarations and signature statements are present.
Roger Jeffs, a director of Axsome Therapeutics (AXSM), reported the sale of 13,464 shares of the company's common stock on 09/02/2025 at a weighted average price of $123.68 per share. The sales were executed as the final transactions under a pre-approved 10b5-1 plan and represent shares underlying previously exercised stock options. Following the reported disposition, Mr. Jeffs beneficially owns 57,510 shares, held directly.
Axsome Therapeutics, Inc. (AXSM) Form 144 notice reports a proposed sale of 13,464 common shares through Charles Schwab & Co., Inc. on 09/02/2025 on NASDAQ with an aggregate market value of $1,665,162.00. The filing lists the securities being sold as previously acquired by exercise and hold on 03/19/2019 (9,514 shares) and 11/19/2021 (3,950 shares), with cash payment noted. The filer also discloses five separate sales during August 2025 totaling 96,694 shares with gross proceeds shown for each trade. The notice includes the standard representation attesting no undisclosed material adverse information.
Insider sales under pre-set plan: This Form 4 shows Jeffs Roger, a director of Axsome Therapeutics (AXSM), sold shares pursuant to a pre-approved 10b5-1 plan across three trading days. He disposed of 20,000 shares on 08/27/2025 at a weighted average price of $122.30, 20,000 shares on 08/28/2025 at $121.60, and 20,000 shares on 08/29/2025 at $121.27. The reported beneficial ownership fell from 110,974 shares after the first sale to 70,974 shares after the third sale. The filer signed the form via attorney-in-fact.
Axsome Therapeutics, Inc. (AXSM) Form 144 shows a proposed sale of 20,000 common shares through Charles Schwab & Co., Inc. for an aggregate market value of $2,425,335.00 with an approximate sale date of 08/29/2025 on NASDAQ. The filer reports acquiring the 20,000 shares on 03/19/2019 by exercise and hold from Axsome Therapeutics, Inc., with payment in cash.
The filing also discloses sales by the same person during the past three months: 16,694 shares on 08/22/2025 (gross proceeds $2,004,598.00), and three separate sales of 20,000 shares on 08/26/2025, 08/27/2025, and 08/28/2025 with gross proceeds of $2,400,658.00, $2,446,052.00, and $2,432,004.00 respectively. The filing states total shares outstanding of 49,901,487.
Axsome Therapeutics, Inc. (AXSM) Form 144 notice shows a proposed sale of 20,000 common shares to be executed on 08/28/2025 through Charles Schwab & Co., Inc., with an aggregate market value of $2,432,004.00. The filing reports the filer acquired 14,648 shares on 03/29/2017 and 5,352 shares on 03/19/2019 via exercise and paid cash. It also discloses recent sales by the same person totaling 56,694 shares during August 2025, generating gross proceeds of $6,851,308.00 across sales on 08/22/2025, 08/26/2025, and 08/27/2025. The filing includes a representation that the seller is not aware of undisclosed material adverse information.
Axsome Therapeutics (AXSM) Form 144 notice reports proposed sale of 20,000 common shares through Charles Schwab & Co., with an aggregate market value of $2,446,052.00 and an approximate sale date of 08/27/2025. The issuer has 49,901,487 shares outstanding. The shares being offered were acquired by exercise on 03/15/2017 (3,298 shares) and 03/29/2017 (16,702 shares), paid in cash to Axsome Therapeutics, Inc.
The filing also discloses prior sales by the same account in the past three months: 08/22/2025 sale of 16,694 shares for $2,004,598.00 and 08/26/2025 sale of 20,000 shares for $2,400,658.00, seller address listed as Roger Jeffs at One World Trade Center, New York.
Axsome Therapeutics director Roger Jeffs reported two open-market sales of common stock under a pre-approved 10b5-1 plan. On 08/22/2025 he sold 16,694 shares at a weighted average price of $120.08, and on 08/26/2025 he sold 20,000 shares at a weighted average price of $120.03, for total shares sold of 36,694. After the 08/22 sale he beneficially owned 150,974 shares; after the 08/26 sale he beneficially owned 130,974 shares. The filings state the sold shares were underlying previously exercised options.
Form 144 notice for Axsome Therapeutics, Inc. (AXSM) shows a proposed sale of 20,000 common shares through Charles Schwab & Co., Inc. on 08/26/2025 with an aggregate market value of $2,400,658. The filing lists total outstanding shares of 49,901,487. The shares were originally acquired by exercise and hold on 05/27/2016 (1,298 shares) and 03/15/2017 (18,702 shares) from Axsome Therapeutics, Inc., both paid in cash. The filing also discloses a prior sale on 08/22/2025 of 16,694 shares for $2,004,598 by the seller identified as Roger Jeffs. The notice includes the seller's representation that they are not aware of any undisclosed material adverse information about the issuer.
Form 144 notice for Axsome Therapeutics, Inc. (AXSM) records a proposed sale of 16,694 common shares through Charles Schwab & Co., Inc. on 08/22/2025 on NASDAQ with an aggregate market value of $2,004,598. The filing reports total shares outstanding of 49,901,487. The securities to be sold were acquired by exercise and hold on 09/16/2014 (3,672 shares), 11/19/2015 (9,127 shares) and 05/27/2016 (3,895 shares), each paid in cash. The form states there were no securities sold in the past three months for the account. Several header fields identifying the filer and issuer appear blank in the provided content.